Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sankyo Wishes to Obtain 75% Statin Share: President Shoda
December 22, 2003
- Sales of In Vitro Diagnostics Rose 1.5% in FY2002: JACR
December 22, 2003
- WORLD NEWS IN BRIEF
December 22, 2003
- DIAGNOSTIC NEWS IN BRIEF
December 22, 2003
- Dainippon Sees 3 New Drugs as Potential Blockbusters
December 22, 2003
- Semi-annual Business Results
December 22, 2003
- Japanese Industry to Participate in Negotiations on PPRS: JPMA-ABPI Conference
December 22, 2003
- BULLETIN
December 22, 2003
- BUSINESS NEWS IN BRIEF
December 22, 2003
- Segami Medics Aims for \100 Bil. Sales as Early as Possible
December 22, 2003
- Payers Clash with Healthcare Providers on Medical Fee Revision
December 22, 2003
- OTC NEWS IN BRIEF
December 22, 2003
- 4th Proposal on Special Structural Reform Zones Finalized
December 22, 2003
- MEDICAL DEVICE NEWS IN BRIEF
December 22, 2003
- REGULATORY NEWS IN BRIEF
December 22, 2003
- Malzen to Merge with Shinyakudo in May 2004
December 22, 2003
- Korosho Calls For Measures to Prevent Medical Accidents
December 22, 2003
- Pfizer Japan Reaches "Critical Mass": Mr. Bootes
December 22, 2003
- Report on Measures to Prevent Medical Accidents Compiled by JMA
December 22, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 22, 2003
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…